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A prospective, randomized, double-blind study was 
performed in 40 patients (ASA class 1-111) treated with 
atracurium to ascertain whether histamine release 
caused hemodynamic or cutaneous changes. The 
treated group of 20 patients was premedicated with the 
H, antagonist dimetindene (0.2 mg/kg) and the H, an- 
tagonist ranitidine (1 25 mg/kg); the control group of 
20 patients received saline. Six minutes after the in- 
duction of anesthesia with thiopental/fentanyl, pa- 
tients received atracurium 0.5 mg/kg over 5 s. Plasma 
histamine levels were measured fluorometrically 5 min 
after administration of thiopental/fentanyl and 2 and 
5 min after atracurium. Arterial blood pressure and 
heart rate were recorded every 2 min. Histamine levels 
(0.24 ng/mL) did not change significantly after thio- 
pental/fentanyl. In the control group, 2 min after in- 
jection of atracurium, plasma histamine levels were 
0.76 t 0.76 ng/mL, and in the antihistamine-treated 
group, 0.39 2 0.24 ng/mL (P < 0.05 control versus 
treated), suggesting that pretreatment with antihista- 
mines may attenuate atracurium-induced histamine re- 
lease. Systolic and diastolic blood pressure decreased 
significantly in both groups after thiopental ( P  < 0.05), 
but did not decrease further after the administration of 
atracurium. There were cutaneous manifestations in 7 
of 20 patients in the control group and in none of the 
20 patients treated with H, and H, antagonists (P < 
0.0005). We conclude that atracurium caused modest 
histamine release in our patients but that the decrease 
in arterial blood pressure may have been due, in part, 
to thiopental. Cutaneous manifestations of histamine 
release did not correlate with hemodynamic events or 
with plasma histamine levels, but were prevented with 
antihistamine pretreatment. 
(Anesth Analg 1994;78:967-72) 
M any muscle relaxants, anesthetic drugs, and adjuvants may cause the increase of plasma histamine levels by nonimmunologic mech- 
anisms. Whether patients should be pretreated with 
HI and H2 antagonists to prevent histamine release 
during anesthesia and surgery has been debated for 
20 yr (1). Recently, much of the debate has focused on 
atracurium. Although its formulation does not contain 
solvents that interfere with its action or elicit hista- 
mine release, depending upon dose of atracurium and 
speed of administration, histamine may be released 
(24) .  Administration of atracurium has been associ- 
ated with hypotension and increased plasma hista- 
mine levels (3-51, but the temporal proximity 
of the administration of the drug used for inducing 
anesthesia and atracurium makes interpretation of 
these hemodynamic changes difficult. In addition, 
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thiopental, fentanyl, and atracurium all can induce 
cutaneous reactions, making it unclear whether the 
cutaneous manifestations of histamine release can be 
attributed to atracurium in the clinical setting. We 
performed a double-blind, randomized, placebo-con- 
trolled trial in two groups of 20 patients each to ascer- 
tain whether low levels of histamine release associated 
with atracurium administration would cause sig- 
nificant hemodynamic or cutaneous changes, and 
whether these changes could be attenuated by pro- 
phylactic administration of an antihistamine. Our 
study differs from previous studies (4) in which in- 
creased histamine levels were the source of greatest 
interest, but antihistamines were not used. 
Methods 
After the study was reviewed and authorized by our 
institutional review board, 40 patients were enrolled in 
the study according to the following inclusion criteria: 
age >18 yr, body weight between 50 and 100 kg, and 
preoperative ASA grade 1-111. Patients were scheduled 
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Figure 1. Schedule for drug administra- 
tion and sampling. 
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for elective surgery under general anesthesia. Excluded 
were pregnant or breast-feeding women, patients who 
had taken HI- or H,- receptor antagonists or cortico- 
steroids up to 1 wk before surgery, and patients with a 
history of atopy, asthma, or previous reactions after in- 
travenous medication. All patients gave their written 
informed consent. Except for one total gastrectomy, all 
operations were minor surgical procedures, in order to 
minimize parenteral histamine release from surgical 
manipulations. 
Patients were randomly allocated by a random num- 
ber table to the treated (H, + H2) or to the control group 
on the morning of the operation. The evening before, 
and on the morning of surgery, all patients were pre- 
medicated with oral lormetazepam (1-2 mg per DS) ,  a 
drug not associated with histamine release. An anes- 
thetic nurse injected coded solutions (H, + H, or con- 
trol) into an infusion bottle containing 50 mL of saline 
0.9% to guarantee the double-blind condition and the 
stability of the drug mixture. The H, antagonist dimet- 
indene (0.2 mg/kg) and the H, antagonist ranitidine 
(1.25 mg/kg) or equal volumes of control solution were 
administered as a slow infusion 14 to 18 min before 
injection of atracurium to permit adequate antagonism 
and minimize the possibility of increase in plasma lev- 
els of histamine due to dimetindene and ranitidine. An- 
esthesia was induced with fentanyl (3 pg/kg intrave- 
nously) and thiopental(4 mg/kg intravenously over 30 
s) and maintained with enflurane (0.4%-1% inspired 
concentration), N,O/O,. Atracurium (0.5 mg/kg) was 
given 6 min after thiopental as a bolus injection over 5 
s. The trachea was intubated 6 min after injection of 
atracurium. Hemodynamic and clinical variables were 
measured every 2 min for technical reasons and blood 
samples for histamine determination were taken before 
(baseline) and after premedication, 5 min after thio- 
pental (1 min before atracurium), 2 and 5 min after 
atracurium, and 4 min after intubation (Figure 1, 
Sample 6). 
Plasma histamine concentrations were measured 
using the fluorometric-enzymatic method. This assay 
has a sensitivity of 20 pg/rnL (6,7). None of the drugs 
or drug formulations interfered with the fluorometric 
assay at concentrations up to mol/L. 
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Heart rate was measured by electrocardiogram (lead 
11) via a Siemens monitor. Arterial blood pressure (sys- 
tolic, diastolic) was measured using an oscillometer 
and was documented every 2 min (three times each 
after thiopental and after atracurium). Cutaneous 
manifestations of histamine release were assessed by 
an investigator blinded to the study. Skin changes were 
graded as flush, constant redness (if longer than 120 s), 
erythema, or wheals. 
Rank paired t-test was used to compare continuous 
variables within a group, and unpaired t-test was used 
for intergroup comparisons. Data are presented as 
mean 2 SD. Noncontinuous variables were analyzed by 
Fisher’s exact test. We used the criteria of Lorenz and 
Neugebauer (6) to establish causality. This analysis 
considers the problem of attribution of causality 
(i.e., histamine release, cutaneous or hemodynamic 
changes) during a sequence of events (drug adminis- 
tration, intubation). 
Results 
There were no significant differences between the 
treated and control groups in age (36 [22-711 yr treated 
vs 35 [18-541 yr control), gender (16 males treated vs 13 
males control), weight, type of procedure (predomi- 
nantly general surgery > orthopedic > urology), or ASA 
classification, except two patients in the antihistamine 
group were ASA grade 111. 
Systolic blood pressure decreased significantly after 
thiopental/fentanyl nitrous oxide and enflurane in 
both groups (Figure 2). In the control group, mean sys- 
tolic blood pressure decreased from 135 mm Hg to 103 
mm Hg, and in the treated group from 147 to 105 mm 
Hg, but there were no significant differences between 
groups. Upon administration of the first dose of atra- 
curium, there was no statistically detectable further de- 
crease in systolic blood pressure. Diastolic changes mir- 
rored systolic changes. In the control group, no patient 
exhibited a decrease in systolic blood pressure of >20% 
after the administration of atracurium. In the 
antihistamine-pretreated group, systolic blood pres- 
sure decreased >20% in two patients, one of whom ex- 
perienced coincident histamine release (Table 1). In this 
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Figure 2. Box plot of systolic blood pressure for control and anti- 
histamine-treated groups. This format presents the first and third 
quartiles as top and bottom of box, median as middle line, and 90th 
percentile as whiskers. Outlying points (<2 SD) are given by open 
circles. Although there was a significant decrease in systolic blood 
pressure in both placebo and antihistamine-treated groups after 
thiopental ( P  < 0.05), no further change was seen after atracurium in 
either group. 
patient (no. 16), systolic blood pressure decreased after 
thiopental administration from 150 to 100 mm Hg, and 
subsequently after atracurium administration to 93 
mm Hg. These hemodynamic changes were associated 
with an increase in plasma histamine levels from 0.21 
ng/mL to 2.31 ng/mL 2 min after atracurium, and 1.55 
ng/mL 3 min later. No change in heart rate was de- 
tected in this patient. 
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In the control group, heart rate increased >20% in 
five patients and decreased >20% in two patients after 
thiopental and fentanyl administration. Heart rate re- 
mained unchanged in 11 patients. After atracurium, 
heart rate did not change in either group (Table 1, Fig- 
ure 3). In the antihistamine-treated group mean heart 
rate decreased from 85.5 % 2.5 beats/min to 70.4 f_ 2.4 
beats/min after thiopental ( P  < 0.001) and further 
decreased to 64.6 2 1.7 beats/min after atracurium 
( P  < 0.001). After intubation the heart rate increased to 
84.6 f 3.1 beats/min ( P  < 0.005 vs previous value). 
Values for the control group were virtually identical. 
Differences in heart rate were not statistically different 
between groups for similar intervals. 
The mean plasma histamine concentration in the 
control and antihistamine-treated groups was virtually 
identical (0.24 -+ 0.13 and 0.24 2 0.10 ng/mL) and re- 
mained statistically unchanged after thiopental admin- 
istration (Figure 4). The mean concentration 2 min after 
the administration of atracurium was 0.76 2 0.76 
ng/mL in the control group and 0.39 2 0.24 ng/mL in 
the antihistamine-treated group (P < 0.04 vs control 
group; P < 0.02 versus prior sample). 
Although plasma histamine levels remained in the 
physiologic range in both groups, there was a marked 
attenuation of atracurium-induced histamine release in 
the antihistamine-pretreated group (0.76 ? 0.76 vs 0.39 
% 0.24; P < 0.05; Figure 4). When considered on an 
individual basis, histamine release occurred after 
atracurium in 16 patients, 11 in the control group and 
5 in the antihistamine-pretreated group (Table 2). 
Table 1. Arterial Blood Pressure and Heart Rate During Induction of Anesthesia in Relation to Plasma Histamine Levels 
After thiopental4 mg/kg 
and fentanyl3 pg/kg After atracurium 0.5 mg/kg 
Histamine No histamine Histamine No histamine 
release release release release 
Placebo group ( n  = 20) 
Heart rate 
Decrease >20% 
Increase >20% 
Unchanged 
Blood pressure 
Systolic decrease >20% 
Unchanged 
Antihistamine group ( n  = 20Y 
Heart rate 
Decrease >20% 
Increase >20% 
Unchanged 
Blood pressure 
Systolic decrease >20% 
Systolic increase >20% 
Unchanged 
n = 2  n = 18 
0 
1 
1 
2 
2 
5 
11 
13 
5 
n = 20 
6 
3 
11 
17 
0 
3 
n = 12 
0 
0 
12 
0 
12 
n = 5  
0 
0 
5 
1 
0 
4 
n = 8  
0 
0 
8 
0 
8 
n = 15 
0 
0 
15 
1 
1 
13 
Patients were separated according to whether they exhibited hemodynamic response and histamine release. 
' Dimetindene 0.2 mg/kg; ranitidine 1.25 mg/kg. 
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This difference in incidence between control and 
antihistamine-treated groups did not achieve statistical 
significance (2P < 0.11) (Fisher’s exact test). 
Two patients experienced significant increases of 
plasma histamine associated with the administration of 
atracurium. Aside from the patient described above, in 
one patient (No. 31) systolic blood pressure decreased 
from 145 to 126 mm Hg associated with the induction 
of anesthesia. No further hemodynamic changes were 
noted after atracurium administration in the patient, 
although the plasma histamine level increased from 
0.22 ng/mL after thiopental to 3.34 ng/mL 2 min after 
atracurium, with a level of 1.74 ng/mL 3 min later. In 
this patient, heart rate increased 12 beats/min after 
thiopental administration, and an additional 12 beats/ 
min after the administration of atracurium. In general, 
changes in heart rate appeared to be unrelated to his- 
tamine levels (Table 1). Heart rate did not decrease in 
the control group after the administration of atra- 
curium, even with modestly increased plasma hista- 
mine levels. 
We examined data regarding cutaneous manifesta- 
tions by segregating patients who developed cutane- 
ous signs from both the control and antihistamine- 
treated groups. In the control group, seven patients 
developed cutaneous signs after atracurium adminis- 
tration. Six patients demonstrated no cutaneous signs 
of histamine release despite an increase in plasma lev- 
els (Table 2). The remaining seven patients in the con- 
trol group did not demonstrate an increase in plasma 
histamine concentrations or cutaneous signs (not 
included in Table 2). Plasma histamine levels of 
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Figure 4. Box plot of plasma histamine of log histamine concentra- 
tion at baseline and after drug administration. This format presents 
the first and third quartiles as top and bottom of box, median as 
middle line, and 90th percentile as whiskers. Outlying points (>2 SD) 
are given by open circles. Differences between intervals and groups 
are as indicated in the figure. 
cutaneous reactors and nonreactors were not signifi- 
cantly different. In the antihistamine-pretreated group, 
none of the 20 patients experienced cutaneous signs of 
histamine release, but five patients showed an increase 
in plasma histamine levels from a mean of 0.23 ? 0.09 
to 0.71 2 0.23 ng/mL (P < 0.0005 vs control). The dif- 
ference between placebo and antihistamine pretreat- 
ment in incidence of cutaneous signs was statistically 
significant (2P = 0.008, Fisher’s exact test). The corre- 
sponding differences in incidence of elevated plasma 
histamine (11/20 vs 5/20) were in the same direction 
but did not achieve statistical significance (2P = 0.11, 
Fisher’s exact test). 
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Figure 3. Box plot of heart rate for control of placebo and antihis- 
tamine groups. This format presents the first and third quartiles as 
top and bottom of box, median as middle line, and 90th percentile 
as whiskers. Outlying points (>2 SD) are given by open circles. 
Although there was a significant decrease in heart rate after thio- 
pental ( P  < 0.001) and a significant increase in heart rate after 
tracheal intubation ( P  < 0.001), these differences were the same in 
both the control and antihistamine-treated groups. 
Discussion 
Atracurium is a known histamine releaser, both in 
vivo and in vitro (4,5,8,9), but the proximity of its 
administration to the induction of anesthesia, as well as 
the speed of injection and dose, must be factors in con- 
sidering the hemodynamic effects. Under our anes- 
thetic regimen, in which thiopental and atracurium 
administration were widely separated, bolus adminis- 
tration of atracurium elicited only modest elevations in 
plasma histamine and these were without significant 
hemodynamic changes, even in the control group. 
Hosking et al. (8) demonstrated the efficacy of 
combined HI- and H,-receptor block in attenuating 
atracurium-induced hemodynamic affects. However, 
in their study the atracurium dose was 1.5 mg/kg, ap- 
proximately three times the normal dose for endotra- 
cheal intubation, and the associated plasma histamine 
levels were very high. In a study by Gallo et al. (5), 
atracurium was given so soon after thiopental that it 
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Table 2. Plasma Histamine Levels of Patients With and Without Cutaneous Signs Who Exhibited Histamine 
Release After Atracurium 
Plasma histamine Plasma histamine 
(ng/mL) prior (ng/mL) 2 min Cutaneous 
Patient No. to atracurium after atracurium signs 
Control group (n  = 6): plasma histamine concentration in patients without cutaneous signs 
2 0.34 0.68" 
7 0.36 0.58" 
10 
11 
16 
21 
Mean 
0.29 
0.14 
0.21 
0.17 
0.25 2 0.09 
0.75" 
1.04" 
2.31" 
0.47" 
1.09 C 0.68 
Control group (n  = 7): plasma histamine concentration in patients with cutaneous signs 
6 0.65 0.86" CR 
14 0.06 0.66" FL 
23 0.05 0.17 CR,ER 
24 0.23 0.60" ER 
31 0.22 3.34" ER 
33 0.05 0.29 FL,ER 
39 0.11 0.81 * ER 
Mean 0.20 2 0.20 0.96 5 1.08 
Antihistamine group ( n  = 5): plasma histamine concentration in patients without cutaneous signs 
13 0.38 0.86a 0 
20 0.22 0.68" 0 
26 0.17 0.55" 0 
32 0.16 0.44" 0 
40 0.24 1.02" 0 
Mean 0.23 -C 0.09 0.71 2 0.23 
CR = constant redness; ER = erythema (spots); FL = flush. 
Responder according to Lorenz and Neugebauer (6). 
was difficult to discriminate between hemodynamic ef- 
fects of the induction drug and atracurium. Other stud- 
ies involving atracurium's effects on isolated organs 
and tissues reflect the functional heterogeneity of mast 
cells between species (10,ll). We therefore designed 
our study to explore the effects of atracurium-induced 
histamine release using the customary dose 0.5 mg/kg 
but under conditions that allowed us to discriminate 
between the effects of thiopental and the relaxant. 
Based on our clinical experience and previous stud- 
ies (5),  we questioned whether the administration of 
atracurium at intubating doses was associated with hy- 
potension and or cutaneous manifestations. Surpris- 
ingly, in our study, atracurium did not cause a further 
reduction in arterial blood pressure. Whether atra- 
curium, when given in rapid sequence after the ad- 
ministration of thiopental and fentanyl, elicits a more 
profound hemodynamic change was not examined, al- 
though the study by Gallo et al. (5) suggests that this 
is the case. Because the hypotension we observed 
was related temporarily to thiopental and preceded 
atracurium administration, it presumably reflected 
barbiturate-mediated cardiac depression and was 
perhaps more apparent due to an experimental design 
in which intubation and its attendant stress were 
delayed. 
Another clinical problem associated with the admin- 
istration of atracurium is the appearance of local or 
systemic cutaneous manifestations, including redness, 
urticaria, wheals, and flush. In our study there was no 
relationship between plasma histamine levels achieved 
after atracurium and cutaneous manifestations. Six pa- 
tients with modest elevations in plasma histamine lev- 
els experienced no cutaneous signs, whereas seven 
other patients with virtually identical levels experi- 
enced cutaneous signs (Table 2). The remaining seven 
patients had no increase in plasma levels and no cu- 
taneous signs. The functional heterogeneity of mast 
cells could account for such differences. Previous stud- 
ies using human mast cells from skin and lung tissue 
have demonstrated fundamental differences in the sus- 
ceptibility of these cells to release histamine in response 
to atracurium. It may well be that plasma histamine 
levels are a poor reflection of the effect of drugs on skin 
mast cells (11,12). None of our antihistamine-pretreated 
patients had any cutaneous manifestations associated 
with atracurium administration, although five had 
modest increases in plasma histamine levels (Table 2). 
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Our data, therefore, suggest that the cutaneous mani- 
festations associated with atracurium administration in 
usual doses are unlikely to be related to systemic he- 
modynamic changes or plasma histamine levels. How- 
ever, these skin changes probably reflect local release of 
histamine because they are prevented by pretreatment 
with antihistamines. 
Histamine can be released at low levels in a signifi- 
cant number of patients, perhaps without the full ap- 
preciation of the attending anesthesiologist. In the con- 
trol group, six patients had elevations of plasma 
histamine levels, including one patient who achieved 
a level of 2.31 ng/mL without significant hemody- 
namic or cutaneous manifestations. It is therefore dif- 
ficult for an anesthesiologist to judge whether the hy- 
potension that occurs during the course of a normal 
anesthetic is secondary to histamine release, ganglionic 
block, or a variety of other side effects associated with 
anesthetic drugs and adjuvants. It is clear, however, 
from our results and other studies, that chemoprophy- 
laxis with HI and H, antagonists can attenuate some of 
the clinical manifestations of histamine release, par- 
ticularly rash and flush (13-16). 
Although the receptor antagonist properties of an- 
tihistamines are the main contributory factors in at- 
tenuating the cardiovascular effects of histamine re- 
lease (13-16), our study also demonstrates their effect 
on histamine levels. ln our patients, the measured level 
of plasma histamine was significantly lower in the 
antihistamine-pretreated group. A series of studies in 
isolated mast cells and tissues has shown that super- 
fused histamine will attenuate chemically induced re- 
lease (11,12,17,18). Our findings that histamine release 
is inhibited by antihistamines differ from those of 
Hoslungs et al. (81, but both the absolute and evoked 
levels of histamine we observed were considerably 
less. 
Although the presence of a rash after atracurium ad- 
ministration has been taken as a harbinger of signifi- 
cant cardiovascular changes, our experimental data 
suggest that this is not the case. Cutaneous manifes- 
tations of atracurium administration were independent 
of systemic levels of plasma histamine and of 
cardiovascular effects in our relatively healthy group 
of patients. 
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